Compare Manhattan Associates Inc (MANH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Neurocrine Biosciences Inc — how do they compare? Manhattan Associates Inc trades at $195 (market cap $11.38B), while Neurocrine Biosciences Inc trades at $151.75 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| MANH | NBIX | |
|---|---|---|
Market Cap | $11.38B | $16.46B |
Sector | Technology | Health |
52-Week High | $220.19 | $185.50 |
52-Week Low | $120.88 | $123.10 |
Enterprise Value | $11.25B | $16.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
